title: Comparison of platinum chromium everolimus-eluting stent with cobalt chromium everolimus-eluting stent in unselected patients undergoing percutaneous coronary intervention.
abstract: OBJECTIVE
  The recent PLATINUM trial has demonstrated that the use of the new generation platinum chromium everolimus-eluting stents (PtCr-EES) yield clinical outcomes similar to those obtained by the use of cobalt chromium everolimus-eluting stents (CoCr-EES) in selected patients with 1 or 2 de novo coronary artery lesions. This study aimed to compare the safety and efficacy of the PtCr-EES and CoCr-EES in unselected patients from a real-life single-center registry.
  
  
  METHODS
  From July 2009 through November 2010, 788 consecutive patients in our institution with symptomatic coronary artery disease who were treated with the CoCr-EES (n = 410) or PtCr-EES (n = 378) were enrolled into this study. The primary endpoint of the study was target-lesion failure (TLF) at 12-month follow-up and the secondary endpoints were major adverse cardiovascular events and stent thrombosis.
  
  
  RESULTS
  The prevalence of TLF in the PtCr-EES group (4.5%) was similar to that in the CoCr-EES group (3.9%). In addition, there were no significant differences in the 12-month rates of cardiac death (2.1% vs. 1.5%), myocardial infarction (2.4% vs. 3.9%), ischemia-driven target lesion revascularization (2.4% vs. 2.2%), and definite or probable stent thrombosis (0.5% vs. 1.5%, all p > 0.05).
  
  
  CONCLUSIONS
  At 12-month follow-up, the PtCr-EES is comparable in safety and efficacy to the CoCr-EES in unselected patients with coronary artery diseases.
authors.affiliation: Department of Cardiology, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. tanhc2014_11@163.com.
authors.forename: R-G
authors.initials: RG
authors.lastname: Li
authors.forename: C-H
authors.initials: CH
authors.lastname: Lee
authors.forename: A
authors.initials: A
authors.lastname: Low
authors.forename: M
authors.initials: M
authors.lastname: Chan
authors.forename: K H
authors.initials: KH
authors.lastname: Chan
authors.forename: A M
authors.initials: AM
authors.lastname: Richards
authors.forename: X-K
authors.initials: XK
authors.lastname: Qu
authors.forename: W-Y
authors.initials: WY
authors.lastname: Fang
authors.forename: H C
authors.initials: HC
authors.lastname: Tan
mesh_terms: D000368:Aged; D002857:Chromium / Q000592:standards*; D003035:Cobalt / Q000592:standards*; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging* / Q000601:surgery*; D054855:Drug-Eluting Stents / Q000592:standards*; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation / Q000592:standards*; D010984:Platinum / Q000592:standards*; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D002857:Chromium; D003035:Cobalt; D010984:Platinum; D000068338:Everolimus